Press Releases GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 19:35:01 06/03/2026 +03			5-day change	1st Jan Change
2,038.00 ^GBX	-1.83%		-7.41%	+11.70%

03-05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
03-05	GSK outgoing CEO Emma Walmsley's 2025 total remuneration was 15.7 mln pounds vs 10.6 mln pounds in 2024 - annual report	RE

Press Releases

03-05	GSK : Governance And Remuneration Report 2025	PU
03-05	GSK : Responsible Business Report 2025	PU
03-05	GSK : Cautionary statement 2025	PU
03-03	GSK : completes acquisition of RAPT Therapeutics	PU
02-27	GSK plc - Linerixibat accepted for priority review in China for cholestatic pruritus in patients with primary biliary cholangitis	AQ
02-26	GSK enters agreement to acquire 35Pharma Inc.	AQ
02-25	GSK : ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen	PU
02-25	GSK : ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing	PU
02-23	Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract	BU
02-19	GSK : ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM	PU
02-18	GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows	BU
02-18	GSK plc - Exdensur approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps	AQ
02-17	GSK : Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows	PU
02-10	GSK : RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older	PU
02-05	GSK : FY 2025 results transcript	PU
02-04	Glaxo: Q4 Earnings Snapshot	AQ
02-04	GSK : Full results	PU
02-04	GSK : FY 2025 results slides	PU
02-04	GSK : FY 2025 pipeline assets and clinical trials report	PU
02-04	GSK : FY 2025 results infographic	PU
02-04	GSK : FY 2025 US dollar translation	PU
02-04	GSK : delivers strong 2025 performance and re-affirms long-term outlooks	PU
01-26	GSK : RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older	PU
01-23	GSK : Trelegy Ellipta approved in China for use in adults with uncontrolled asthma	PU
01-21	GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026	BU